This article is more than 5 years old. Information may no longer be current.
Oritavancin efficacy similar to vancomycin for treating ABSSSI
Click Here to Manage Email Alerts
DENVER — A single-dose of investigational oritavancin had similar efficacy compared with 7 to 10 days of use of vancomycin, researchers reported here at the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy.
“What is unique about this study is it is testing an antibiotic where the full course of treatment has been given to the patient through one administration,” Ralph Corey, MD, professor of medicine and infectious disease at Duke University, said in a press release. “This study shows that a single 1,200-mg dose of oritavancin (Medicines Company) was noninferior to 7 to 10 days of vancomycin in treating [acute bacterial skin and skin structure infections] caused by gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). It was well-tolerated, with a safety profile similar to vancomycin.”
Ralph Corey
The study included 968 adults with acute bacterial skin and skin structure infections (ABSSSI) receiving either a single 1,200-mg dose of oritavancin (n=475) or 7 to 10 days of treatment with vancomycin (n=479).
Researchers found that at 48 and 72 hours, oritavancin was similar in early clinical evaluation response (82.3%) compared with vancomycin (78.9%). Oritavancin (86.9%) was also similar for the number of participants reaching a 20% or greater reduction in lesion from baseline compared with vancomycin (82.9%). Cure with vancomycin (80%) at 7 to 10 days after treatment was similar compared with oritavancin (79.6%).
Sixty percent of oritavancin participants reported at least one adverse event compared with 63.8% of vancomycin participants. Treatment-emergent adverse events were reported in 22.8% of oritavancin participants compared with 31.4% of vancomycin participants. Fewer skin and subcutaneous adverse events were reported in oritavancin participants (11.6%) compared with 19.1% of vancomycin participants.
“The benefit of an early, definitive and aggressive treatment strategy in seriously infected patients warrants additional study in skin and other severe infections, including those requiring prolonged periods of treatment,” Corey said.
For more information:
Corey R. Abstract #L-204. Presented at: ICAAC 2013; Sept. 9-13, 2013; Denver.
Disclosure: Corey serves as a consultant for various pharmaceutical manufacturers. Please see abstract for full list of disclosures.